

Jaclyn Frances Hechtman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8447373/publications.pdf>

Version: 2024-02-01

86
papers

10,178
citations

101543

36
h-index

54911

84
g-index

87
all docs

87
docs citations

87
times ranked

16427
citing authors

#	ARTICLE	IF	CITATIONS
1	Carcinomas assemble a filamentous CXCL12â€“keratin-19 coating that suppresses T cellâ€“mediated immune attack. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	32
2	Defining and Targeting Esophagogastric Cancer Genomic Subsets With Patient-Derived Xenografts. JCO Precision Oncology, 2022, 6, e2100242.	3.0	5
3	Same-Cell Co-Occurrence of RAS Hotspot and BRAF V600E Mutations in Treatment-Naive Colorectal Cancer. JCO Precision Oncology, 2022, 6, e2100365.	3.0	1
4	TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors. Cancer Discovery, 2021, 11, 126-141.	9.4	34
5	Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusionâ€“Positive Lung Cancer by Combining Selpercatinib with Crizotinib. Clinical Cancer Research, 2021, 27, 34-42.	7.0	87
6	Characterization and Clinical Outcomes of DNA Mismatch Repairâ€“deficient Small Bowel Adenocarcinoma. Clinical Cancer Research, 2021, 27, 1429-1437.	7.0	23
7	A Performance Comparison of Commonly Used Assays to Detect RET Fusions. Clinical Cancer Research, 2021, 27, 1316-1328.	7.0	39
8	Current Management of Appendiceal Neoplasms. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, 118-132.	3.8	18
9	Reply to Singh et al.. Modern Pathology, 2021, 34, 1033-1034.	5.5	1
10	<i>EGFR</i> Amplification in Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2021, 113, 1561-1569.	6.3	12
11	Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways. Clinical Cancer Research, 2021, 27, 3491-3498.	7.0	8
12	Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. Nature Communications, 2021, 12, 3770.	12.8	68
13	Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer. JAMA Network Open, 2021, 4, e2114753.	5.9	15
14	Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma. Hepatology, 2021, 74, 1429-1444.	7.3	73
15	Pan-Cancer Biomarkers: Changing the Landscape of Molecular Testing. Archives of Pathology and Laboratory Medicine, 2021, 145, 692-698.	2.5	10
16	NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Modern Pathology, 2020, 33, 38-46.	5.5	373
17	Reliable Clinical MLH1 Promoter Hypermethylation Assessment Using a High-Throughput Genome-Wide Methylation Array Platform. Journal of Molecular Diagnostics, 2020, 22, 368-375.	2.8	25
18	Retained mismatch repair protein expression occurs in approximately 6% of microsatellite instability-high cancers and is associated with missense mutations in mismatch repair genes. Modern Pathology, 2020, 33, 871-879.	5.5	58

#	ARTICLE	IF	CITATIONS
19	TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations. <i>Clinical Cancer Research</i> , 2020, 26, 1624-1632.	7.0	103
20	Discordant DNA mismatch repair protein status between synchronous or metachronous gastrointestinal carcinomas: frequency, patterns, and molecular etiologies. <i>Familial Cancer</i> , 2020, 20, 201-213.	1.9	8
21	Molecular epidemiology of IDH2 hotspot mutations in cancer and immunohistochemical detection of R172K, R172G, and R172M variants. <i>Human Pathology</i> , 2020, 106, 45-53.	2.0	13
22	First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 821-831.	10.7	243
23	Lineage Reversion Drives WNT Independence in Intestinal Cancer. <i>Cancer Discovery</i> , 2020, 10, 1590-1609.	9.4	52
24	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal Anal Task Forces whitepaper. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 757-770.	27.6	218
25	Regorafenib in Combination with First-Line Chemotherapy for Metastatic Esophagogastric Cancer. <i>Oncologist</i> , 2020, 25, e68-e74.	3.7	10
26	Somatic HNF1A mutations in the malignant transformation of hepatocellular adenomas: a retrospective analysis of data from MSK-IMPACT and TCGA. <i>Human Pathology</i> , 2019, 83, 1-6.	2.0	14
27	Resistance to TRK inhibition mediated by convergent MAPK pathway activation. <i>Nature Medicine</i> , 2019, 25, 1422-1427.	30.7	144
28	Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6160-6169.	7.0	73
29	Genomic stratification beyond Ras/Raf in colorectal liver metastasis patients treated with hepatic arterial infusion. <i>Cancer Medicine</i> , 2019, 8, 6538-6548.	2.8	8
30	V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer. <i>Cancer Discovery</i> , 2019, 9, 1182-1191.	9.4	27
31	Colorectal carcinoma with double somatic mismatch repair gene inactivation: clinical and pathological characteristics and response to immune checkpoint blockade. <i>Modern Pathology</i> , 2019, 32, 1551-1562.	5.5	12
32	Detection of NTRK Fusions: Merits and Limitations of Current Diagnostic Platforms. <i>Cancer Research</i> , 2019, 79, 3163-3168.	0.9	138
33	Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response. <i>Science</i> , 2019, 364, 485-491.	12.6	395
34	The past, present, and future of HER2 (ERBB2) in cancer: Approaches to molecular testing and an evolving role in targeted therapy. <i>Cancer Cytopathology</i> , 2019, 127, 428-431.	2.4	1
35	Efficacy of Combined VEGFR1-3, PDGF α / β , and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3811-3817.	7.0	10
36	Cellular localization of PD-L1 expression in mismatch-repair-deficient and proficient colorectal carcinomas. <i>Modern Pathology</i> , 2019, 32, 110-121.	5.5	28

#	ARTICLE	IF	CITATIONS
37	Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. <i>JAMA Oncology</i> , 2019, 5, 471.	7.1	426
38	<i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i> -Amplified Esophagogastric Cancer. <i>Cancer Discovery</i> , 2019, 9, 199-209.	9.4	115
39	Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions. <i>Cancer Research</i> , 2019, 79, 1047-1053.	0.9	112
40	Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 967-976.	7.0	164
41	Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies. <i>Clinical Cancer Research</i> , 2019, 25, 2116-2126.	7.0	390
42	FOLFICIS Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer. <i>Clinical Colorectal Cancer</i> , 2019, 18, e39-e52.	2.3	21
43	Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. <i>Cancer Cell</i> , 2018, 33, 125-136.e3.	16.8	589
44	Immunohistochemical null-phenotype for mismatch repair proteins in colonic carcinoma associated with concurrent MLH1 hypermethylation and MSH2 somatic mutations. <i>Familial Cancer</i> , 2018, 17, 225-228.	1.9	17
45	Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. <i>Cancer Discovery</i> , 2018, 8, 49-58.	9.4	275
46	Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 2027-2033.	1.5	19
47	Germline <i>SDHA</i> mutations in children and adults with cancer. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a002584.	1.2	33
48	Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies. <i>Journal of Clinical Investigation</i> , 2018, 128, 3819-3825.	8.2	45
49	MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation. <i>Nature Communications</i> , 2017, 8, 14674.	12.8	53
50	Chromosome 20q Amplification Defines a Subtype of Microsatellite Stable, Left-Sided Colon Cancers with Wild-type RAS/RAF and Better Overall Survival. <i>Molecular Cancer Research</i> , 2017, 15, 708-713.	3.4	24
51	Universal screening for microsatellite instability in colorectal cancer in the clinical genomics era: new recommendations, methods, and considerations. <i>Familial Cancer</i> , 2017, 16, 525-529.	1.9	18
52	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <i>Nature Medicine</i> , 2017, 23, 703-713.	30.7	2,473
53	Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations. <i>Clinical Cancer Research</i> , 2017, 23, 4753-4760.	7.0	56
54	Diagnosing colorectal medullary carcinoma: interobserver variability and clinicopathological implications. <i>Human Pathology</i> , 2017, 62, 74-82.	2.0	17

#	ARTICLE	IF	CITATIONS
55	Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 244-254.	2.8	96
56	Morphological characterization of colorectal cancers in The Cancer Genome Atlas reveals distinct morphologyâ€“molecular associations: clinical and biological implications. <i>Modern Pathology</i> , 2017, 30, 599-609.	5.5	74
57	Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. <i>Cancer Research</i> , 2017, 77, 6513-6523.	0.9	58
58	Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions. <i>American Journal of Surgical Pathology</i> , 2017, 41, 1547-1551.	3.7	353
59	Clinical and genetic determinants of ovarian metastases from colorectal cancer. <i>Cancer</i> , 2017, 123, 1134-1143.	4.1	43
60	Subclinical focal cholangitis mimicking liver metastasis in asymptomatic patients with history of pancreatic ductal adenocarcinoma and biliary tree intervention. <i>Cancer Imaging</i> , 2017, 17, 21.	2.8	4
61	Characterization of Ntrk fusions and Therapeutic Response to Ntrk Inhibition in Hematologic Malignancies. <i>Blood</i> , 2017, 130, 794-794.	1.4	0
62	Recurrent, truncating <i>SOX9</i> mutations are associated with <i>SOX9</i> overexpression, <i>KRAS</i> mutation, and <i>TP53</i> wild type status in colorectal carcinoma. <i>Oncotarget</i> , 2016, 7, 50875-50882.	1.8	26
63	ARID1A expression in early stage colorectal adenocarcinoma: an exploration of its prognostic significance. <i>Human Pathology</i> , 2016, 53, 97-104.	2.0	18
64	Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma. <i>Modern Pathology</i> , 2016, 29, 1433-1442.	5.5	144
65	Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF. <i>Molecular Cancer Research</i> , 2016, 14, 296-301.	3.4	46
66	A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with <i>ROS1</i> -Rearranged Lung Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2351-2358.	7.0	141
67	EBV-associated lymphoepithelioma-like carcinoma of the pancreas: Case report with targeted sequencing analysis. <i>Pancreatology</i> , 2015, 15, 302-304.	1.1	13
68	Neurogenic Polyps of the Gastrointestinal Tract: A Clinicopathologic Review With Emphasis on Differential Diagnosis and Syndromic Associations. <i>Archives of Pathology and Laboratory Medicine</i> , 2015, 139, 133-139.	2.5	16
69	Additional Primary Malignancies in Patients with Gastrointestinal Stromal Tumor (GIST): A Clinicopathologic Study of 260 Patients with Molecular Analysis and Review of the Literature. <i>Annals of Surgical Oncology</i> , 2015, 22, 2633-2639.	1.5	46
70	Sequencing of 279 cancer genes in ampullary carcinoma reveals trends relating to histologic subtypes and frequent amplification and overexpression of ERBB2 (HER2). <i>Modern Pathology</i> , 2015, 28, 1123-1129.	5.5	51
71	AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants. <i>Molecular Cancer Research</i> , 2015, 13, 1003-1008.	3.4	20
72	Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT). <i>Journal of Molecular Diagnostics</i> , 2015, 17, 251-264.	2.8	1,566

#	ARTICLE	IF	CITATIONS
73	Novel oncogene and tumor suppressor mutations in <i>KIT</i> and <i>PDGFRA</i> wild type gastrointestinal stromal tumors revealed by next generation sequencing. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 177-184.	2.8	28
74	Multiple Endocrine Neoplasia Type 1 Associated With a New Mutation in the Menin Gene and a Midgut Neuroendocrine Tumor. <i>Pancreas</i> , 2014, 43, 145-146.	1.1	5
75	Intraductal Polypoid Lipid-Rich Neuroendocrine Tumor of the Pancreas with Entrapped Ductules: Case Report and Review of the Literature. <i>Endocrine Pathology</i> , 2013, 24, 30-35.	9.0	5
76	Promyelocytic leukemia zinc finger and histone H1.5 differentially stain low- and high-grade pulmonary neuroendocrine tumors: a pilot immunohistochemical study. <i>Human Pathology</i> , 2013, 44, 1400-1405.	2.0	21
77	Mycobacterial pseudotumor of the plantar fascia: how common is it?. <i>Clinical Imaging</i> , 2013, 37, 802-805.	1.5	4
78	Corpora amylacea in gastrointestinal leiomyomas: a clinical, light microscopic, ultrastructural and immunohistochemical study with comparison to hyaline globules. <i>Journal of Clinical Pathology</i> , 2013, 66, 951-955.	2.0	3
79	Intramuscular corpora amylacea adjacent to ileal low-grade neuroendocrine tumours (typical) <i>Tj ETQq1 1 0.784314 rgBT /Overlock 10</i> <i>Pathology</i> , 2013, 66, 569-572.	2.0	5
80	HER2/neu Gene Amplification and Protein Overexpression in Gastric and Gastroesophageal Junction Adenocarcinoma: A Review of Histopathology, Diagnostic Testing, and Clinical Implications. <i>Archives of Pathology and Laboratory Medicine</i> , 2012, 136, 691-697.	2.5	82
81	Anti-Glutamate Receptor 2 as a New Potential Diagnostic Probe for Prostatic Adenocarcinoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2012, 20, 344-349.	1.2	4
82	Carcinoma Ex Microcystic Adenoma of the Pancreas. <i>American Journal of Surgical Pathology</i> , 2012, 36, 305-310.	3.7	23
83	Hepatic Mass in a 73-Year-Old Man. <i>Gastroenterology</i> , 2012, 142, 434-679.	1.3	0
84	Thymomas diagnosed during pregnancy: two cases in young women without paraneoplastic or autoimmune disease. <i>Annals of Diagnostic Pathology</i> , 2012, 16, 392-396.	1.3	7
85	Hepatocellular Carcinoma Arising in a Pigmented Telangiectatic Adenoma With Nuclear β -catenin and Glutamine Synthetase Positivity. <i>American Journal of Surgical Pathology</i> , 2011, 35, 927-932.	3.7	37
86	Ischemic bowel due to embolization from an isolated mobile thrombus of the ascending aorta: a case report and review of the literature. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 32, 238-241.	2.1	10